ArticleExploration of targeted anti-tumor therapy2020

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors.

Rachael Arthur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.